Ikena Oncology, Inc. Common Stock

IKNA XNAS • BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

60M

Short interest (Jul 15)

0.3%

Net Short (Jul 25 ): -0.1%

Borrow Fee

4.25%

↑ 126.4%

Available Shares

↑ 1.5%

Price Chart

Company Overview

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

CIK: 0001835579

Asset Type: CS

Market Data

Market Cap: $59,902,020

Employees: 9

Status: Active

Short Interest

Current Borrow Fee 4.25%

Range: 4.25% - 9.36%

Available Shares 2M

Range: 2.4M - 2.4M

Recent Changes

Fee Change: ↓ 49.5%

Available Change: ↓ 7.7%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime